33394
document
Sivelestat sodium hydrate improves septic acute lung injury by reducing alveolar dysfunction . Sivelestat sodium hydrate ( sivelestat ) is a selective inhibitor of polymorphonuclear leukocyte elastase ( PMN-E ) . We administered sivelestat to patients with septic acute lung injury ( ALI ) to examine its usefulness . The primary endpoints in the study were the duration of artificial ventilation and pulmonary oxygenation ability , and the secondary endpoints were mortality and the concentrations of PMN-E , SP-D , TNF-alpha and IL-8 in blood . In the sivelestat group , the duration of artificial ventilation , pulmonary oxygenation ability , and the blood PMN-E , SP-D , TNF-alpha and IL-8 concentrations decreased significantly . Administration of sivelestat was found to reduce alveolar dysfunction and improve respiratory function , and it was suggested that early administration might be useful .
33395
Intervention_Pharmacological
Sivelestat sodium hydrate
33396
Intervention_Pharmacological
Sivelestat sodium hydrate ( sivelestat )
33397
Intervention_Pharmacological
sivelestat
33398
Intervention_Pharmacological
sivelestat
33399
Intervention_Pharmacological
sivelestat
33400
Outcome_Other
duration of artificial ventilation
33401
Outcome_Physical
pulmonary oxygenation ability
33402
Outcome_Mortality
mortality
33403
Outcome_Other
duration of artificial ventilation
33404
Outcome_Physical
pulmonary oxygenation ability
33405
Outcome_Physical
blood PMN-E , SP-D , TNF-alpha and IL-8 concentrations
33406
Outcome_Physical
alveolar dysfunction
33407
Outcome_Physical
respiratory function
33408
Participant_Condition
septic acute lung injury
33409
Participant_Condition
septic acute lung injury ( ALI )